Marketed Products

LUCENTIS®

Full Prescribing Information (PDF)  /  LUCENTIS® Product Site

LUCENTIS® (ranibizumab injection) marketed by Genentech/Roche and Novartis, is the first marketed therapeutic product manufactured under XOMA’s license using XOMA’s bacterial cell expression technology.  LUCENTIS® received U.S. FDA approval for the treatment of neovascular wet age-related macular degeneration (wet AMD), a leading cause of blindness in people over the age of 55 in the U.S.  

LUCENTIS® is an antibody fragment designed to bind and inhibit VEGF-A, a protein that is believed to play a critical role in the formation of new blood vessels.  In wet AMD, these blood vessels grow under the retina and leak blood and fluid causing rapid damage to the macula, the portion of the eye responsible for fine, detailed central vision.

AMD is a major cause of gradual or sudden, painless, central visual loss in the elderly, brought on by deterioration of the macula. There are two forms of AMD wet and dry. Approximately 1.7 million Americans have the advanced form of this condition.

Worldwide sales of Lucentis® in 2008 by Genentech and it's partner Novartis were $1.76 billion. XOMA earns royalties on these product sales.

CIMZIA®

Full Prescribing Information /  CIMZIA® Product Site

CIMZIA® (certolizumab pegol) marketed by UCB.S.A, is the second marketed product manufactured under XOMA’s license using XOMA’s bacterial cell expression technology.  CIMZIA® received FDA approval in April 2008 for the treatment of Crohn’s disease.  In May 2009, UCB received FDA approval for CIMZIA® for the treatment of moderate to severe rheumatoid arthritis (RA).  CIMZIA® is also in clinical trials for the treatment of psoriasis.

CIMZIA® is an antibody fragment that blocks Tumor Necrosis Factor (TNF) alpha.  

Crohn’s disease is chronic debilitating autoimmune disease that occurs when the immune system inappropriately attacks the gastrointestinal (GI) tract, causing GI symptoms and complications outside the GI tract.  The disease affects approximately 500,000 Americans.

RA is a systemic debilitating autoimmune disease that occurs when the immune system inappropriately attacks joint tissue, causing painful chronic inflammation and irreversible destruction of cartilage, tendons and bones, that often results in chronic pain, loss of function and disability, and can also lead to cardiovascular and pulmonary complications. The disease affects more than two million Americans.

XOMA receives royalties on CIMZIA® sales.

- - -

The above information should not be used as a source for prescribing information.